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Abstract
Background: The influence of prior seasonal influenza vaccination on the antibody response produced by natural infection
or vaccination is not well understood.
Methods:We compared the profiles of antibody responses of 32 naturally infected subjects and 98 subjects vaccinated with
a 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine (FocetriaH, Novartis), with and without a history of seasonal
influenza vaccination. Antibodies were measured by hemagglutination inhibition (HI) assay for influenza A(H1N1)pdm09
and by protein microarray (PA) using the HA1 subunit for seven recent and historic H1, H2 and H3 influenza viruses, and
three avian influenza viruses. Serum samples for the infection group were taken at the moment of collection of the
diagnostic sample, 10 days and 30 days after onset of influenza symptoms. For the vaccination group, samples were drawn
at baseline, 3 weeks after the first vaccination and 5 weeks after the second vaccination.
Results: We showed that subjects with a history of seasonal vaccination generally exhibited higher baseline titers for the
various HA1 antigens than subjects without a seasonal vaccination history. Infection and pandemic influenza vaccination
responses in persons with a history of seasonal vaccination were skewed towards historic antigens.
Conclusions: Seasonal vaccination is of significant influence on the antibody response to subsequent infection and
vaccination, and further research is needed to understand the effect of annual vaccination on protective immunity.
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Introduction
The first influenza pandemic of the 21st century was caused
by a novel influenza A(H1N1) virus, which was a complex
reassortant virus containing genes from avian, human, and
swine influenza viruses. [1] Hemagglutinin (HA) rapidly and
continuously accumulates mutations to escape recognition by
virus-specific antibodies. To date, epidemics and pandemics of
influenza in humans have been restricted to viruses with subtype
H1, H2, and H3 surface HAs, combined with neuraminidase
proteins (NA) of subtypes N1 and N2. However, sporadic
zoonotic infections with avian influenza viruses of subtypes H5,
H7 and H9 have been documented. [2] The potential diversity
of influenza viruses is larger, as sixteen subtypes of HA and 9
subtypes of NA have been identified in wild waterfowl, that
constitute a reservoir for influenza viruses. [3] The occasional
zoonotic transmissions, and the opportunity for human adapta-
tion of animal influenza viruses through reassortment or
adaptation, constitute a continuous pandemic threat, as illus-
trated by the recent pandemic in 2009. Impact of such a new
introduction is determined in part by the level of pre-existing
immunity in the population. Natural influenza virus infection
elicits a protective immune response, mediated primarily
through neutralizing antibodies directed to host-cell binding
domains on the surface proteins of the infecting strain and
antigenically related viruses. An important question related to
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the emergence of new influenza viruses, however, is the degree
of antigenic mismatch that can be tolerated before virus-
neutralising antibodies are no longer capable of inhibiting
infection. Also, the role of antibodies to other epitopes is poorly
understood. Recently, human monoclonal antibodies against
highly conserved influenza virus epitopes in the stalk region
were discovered with broad neutralizing activity against a wide
spectrum of influenza subtypes. [4,5] Similarly, low level cross-
reactive antibodies that bind to the globular head (HA1) have
been found in some individuals (Baas et al., submitted for
publication). An important question is whether the presence of
such broad non-neutralising antibodies may somehow influence
infection. During the recent pandemic, this discussion was
further triggered because of the observed discrepancy between
the population immunity estimates based on serology and the
observed impact: cross-neutralizing antibodies were found in
persons exposed to historic influenza A(H1N1) strains that were
circulating prior to the emergence of the pandemic influenza
H2N2 strain in 1956/57. [6] Nevertheless, only a small fraction
of persons older than 20 years of age were infected during the
first pandemic wave, suggesting other factors influencing
population susceptibility. [7] Wrammert et al. [8] identified
broadly cross-reactive neutralizing antibodies induced by infec-
tion between the influenza A(H1N1)pdm09, recent seasonal
influenza A(H1N1) strains, as well as influenza A(H1N1)1918,
and avian influenza viruses of subtypes H5N1. Others showed
that seasonal vaccination can induce heterosubtypic neutralizing
antibodies as well. [9,10] Somewhat contrasting with this is the
observation that a history of seasonal vaccination can lead to
lower levels and shorter duration of the strain-specific antibody
responses upon heterologous infection. [11,12].
These findings show that the exposure history of individuals
needs to be considered in order to better understand the role of
antibodies in susceptibility to infection,. A commonly used
measure for determination of protective antibodies induced by
influenza virus infection and vaccination is the hemagglutination
inhibition (HI) assay, where a HI titer $40 has been associated
with 50% protection against influenza virus infection in
susceptible populations. [13] HI assays, however, lack repro-
ducibility between laboratories, for example due to inter-
observer variability in visual read-outs of the agglutination titer
and the nature and quality of the erythrocytes that are used in
the assay. In addition, a practical limitation is the need for high
amounts of virus and serum when antibodies to multiple strains
need to be determined, and a biosafety level II and III working
environment. [13,14] Testing for antibodies by micro-neutral-
ization assay has similar disadvantages, and is not widely
available, thereby limiting their use for comparative studies.
ELISA assays have suffered from lack of specificity, due to
broad cross reactivity when HA antigens are used. Therefore,
we explored alternatives for HI antibody testing, and developed
a protein microarray based assay to measure antibodies to the
HA1 subunit from a wide range of viruses, including seven
recent and historic seasonal H1, H2 and H3 influenza viruses,
the A(H1N1)pdm09 influenza virus, and three avian influenza
viruses. [15] Use of this assay revealed substantial diversity in
the antibody profile of individuals, depending on age, but also
on exposure history and on individual host responses. In this
study, we compared the profile of antibody responses elicited by
natural infection, and vaccination for influenza A(H1N1)pdm09
in healthy adults with and without a history of seasonal
influenza vaccination using the protein microarray.
Materials and Methods
Ethics Statement
Both studies were approved by the appropriate institutional
review boards; the Medical Ethical Review Committee of the St.
Elisabeth Hospital, Tilburg, The Netherlands and the Medical
Ethical Review Committee of the University Medical Centre,
Utrecht. Written informed consent was obtained from the
participant or parents/guardians in case of the children.
Subjects
Vaccination group. We conducted a prospective, longitudi-
nal study from November 2009 through June 2010 at the St.
Elisabeth and TweeSteden Hospital, Tilburg, The Netherlands.
[12] Healthcare workers ($18 years; if pregnant only after 13
weeks of pregnancy) of both hospitals were eligible for inclusion.
Serum samples were collected prior to the first vaccination with a
2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine
(FocetriaH, Novartis), before the second vaccination (three weeks
later) and before the vaccination with trivalent seasonal influenza
vaccine (5 weeks after the second vaccination). Demographic
characteristics (age and sex), seasonal influenza vaccination status,
and comorbidity were collected by means of a short questionnaire.
Two subgroups were made: a group that never received seasonal
vaccination and a group that received seasonal influenza
vaccination annually.
Infection group. We used serum samples from a national
pandemic influenza cohort study. [16] Patients and some of their
household contacts had been diagnosed with influenza during the
active case finding activities instituted in the early phase of the
pandemic. Persons testing positive for influenza A(H1N1)pdm09
by RT-PCR testing of a throat/nose swab were contacted and
asked if they were willing to participate in a national cohort study.
We obtained three samples; the first sample taken between 0 - 5
days after onset of influenza symptoms, the 2nd at 10 days after
onset, and the third sample at around 30 days. We used data on
age, sex, date of onset of illness, and seasonal influenza vaccination
status. Two subgroups were made: a group not receiving regular
vaccination and a group that was regularly vaccinated.
Antibody-titer Determination by Hemagglutination
Inhibition Assay (HI)
Virus specific antibodies were measured by HI assay, using egg-
grown A/California/7/2009 A(H1N1) pandemic virus, and fresh
red blood cells of turkeys in Alsever’s solution (Biotrading, The
Netherlands), according to standard methods. [12] The HI titer
was the reciprocal of the highest dilution of serum that inhibited
virus induced hemagglutination. Titers below the detection limit of
10 were assigned to a value of 5, and 1280 was the end point
titration and also the highest dilution tested. Titers were calibrated
against a candidate International Standard for antibody-titers to
influenza A(H1N1)pdm09 virus. [17].
Antibody Determination by Protein Array (PA)
Antibody titers were determined by PA as previously described.
[15] Briefly serum samples were tested in 2 fold serial dilutions
from 1:20 to 1:2560 on nitrocellulose slides pre-coated with a
selection of recombinant monomeric HA1 proteins (Table 1).
Inter-assay variability was monitored by testing dilutions of a
candidate International Standard for antibody-titers to influenza
A(H1N1)pdm09 virus. [17] Trays with a H1 titer for the
International Standard deviating more than one titer step from
the GMT of all standards in the particular run were rejected.
Microarray slides were scanned using a ScanArray Gx Plus
Antibody Profile Measured by Microarray
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microarray scanner (PerkinElmer) and median spot fluorescence
intensity was determined by using ScanArray Express (version 4.0)
software (PerkinElmer). Titers were calculated from the inflection
point of the titration curve as described. [15] Specificity of
reactivity was determined using subtype-specific rabbit antisera,
sera from persons of different age-groups with exposure to
different seasonal influenza viruses, and supernatants from cloned
human memory B cells. Full details of the array validation have
been published elsewhere.( [15], Baas et al., submitted).
Statistical Analyses
Differences in age and gender between the vaccination and
infection group were tested using the Mann-Whitney and chi-
square test, respectively. Antibody levels were analyzed for both
groups against timing of sampling, age, gender, and vaccination
history, using linear mixed modeling after log-transformation.
Separate analyses were performed in the vaccination and infection
group. Also the interaction between time (three time points) and
seasonal vaccination (yes/no) was entered in the model if
significant. No structure was imposed on the residual (co)variances
of the three repeated titer measurements. Estimated coefficients
and their 95% confidence limits were back-transformed to be
interpretable as geometric mean titers (GMT) and multiplicative
change factors between those GMTs.
A titer rise was defined as a 4-fold or greater increase in
antibody titer between the first sample (with a minimum titer of 40
for PA) and follow-up samples from the same individual.
Seroconversion was defined as an increase from below to above
a titer of 40.
Results
Comparison of Vaccination- and Natural Infection-group
A total of 130 subjects were included, with 98 persons in the
vaccination group and 32 in the natural infection-group. Details of
the study groups are shown in Table 2. The median age of the
vaccination group was 49 years (range, 25 to 66), 35 (35.7%) were
men; 40 subjects (40.8%) had received annual seasonal influenza
vaccination. The naturally infected patients were younger
(p,0.0005) and were more often male (p 0.040) than in the
vaccination group: the median age was 30 years (range, 12 to 66),
18 (56.3%) were men; 15 subjects (46.9%) had regularly been
vaccinated against seasonal influenza virus.
Kinetics of Antibody Response to Influenza
A(H1N1)pdm09
Trends in GMTs at baseline and at the different time points are
shown for both groups in Figure 1. Seventy-two of the 98
vaccinees and 22 of the 32 infected patients showed a titer increase
or seroconversion for the homologous antigen as measured by PA,
and 91 of the 98 vaccinees and 27 of the 32 infected patients as
measured by HI.
When comparing titers against the homologous antigen
A(H1N1)pdm09, GMTs measured by PA were higher than those
measured by HI at all time points in both groups, with no obvious
differences between vaccinees and patients. However, when
stratifying the data according to seasonal vaccination history, a
difference in antibody responses was observed between both
groups. Naturally infected persons with a history of seasonal
vaccination showed a stronger antibody response to
A(H1N1)pdm09 by both HI and PA than persons without a
history of seasonal vaccination. This contrasted with opposite
results in persons who received the pandemic vaccine: vaccinees
with a history of seasonal influenza vaccination showed a less
pronounced response by both methods than persons who were
never vaccinated. Similar to observations for the whole groups, the
magnitude of responses measured by the two techniques also
differed, with highest GMTs measured by PA. The antibody
responses measured by both methods were co-linear, except for
the naturally infected persons with a history of vaccination: here,
the curve for the response measured by PA was steeper, suggesting
a disproportionate increase in non-HI antibodies in this group.
Antibody Expression Profiles
To gain a more detailed understanding of the quality and
composition of the antibody response, we profiled sera against 7
antigens using the PA. The expression profile of the different
antigens in response to natural infection and vaccination against
influenza A(H1N1)pdm09 was analyzed using linear mixed
modeling, with adjustments made for gender and age. A ratio
was calculated to indicate the increment between groups with and
without seasonal vaccination.
Antibody profile in response to influenza A(H1N1)pdm09
virus infection with and without seasonal influenza
vaccination. When comparing change in titer compared to
baseline in the natural infection-group, the greatest increase (fold
change) was observed for the homologous antigen, followed by
1918 and the other H1 antigens. Smaller but significant rises in
antibody titer were observed for all other antigens except H5-
2004. Subjects with a history of seasonal influenza virus
vaccination showed a significantly higher baseline titer for the
historic and recent H1 and H3 influenza antigens, but not for H2
and the avian influenza virus antigens (Figure 2). The natural
infection-group had a greater increase in titer for all antigens than
the vaccination group, although the response in the persons with
seasonal vaccination history was skewed towards seasonal influ-
enza antigens H1-1999 and H1-2007, for which most significant
differences in response were observed. No significant interaction
between time and former seasonal vaccination was found for any
of the antigens in this infection group, adjusted for age and gender.
Absence of this above mentioned interaction coincides with a
model where the time courses of the titers in both vaccination
history subgroups are parallel. (Described in Table S1).
Antibody profile in response to vaccination against
influenza A(H1N1)pdm09 with and without seasonal
influenza vaccination. In persons without a history of seasonal
vaccination, the magnitude of the antibody response (fold change)
was highest for the homologous and the H1-1918 antigens.
Table 1. HA1 antigens used for the microarray.
Name Strain Subtype
H1-1999 A/New Caledonia/20/99 H1N1
H1-2007 A/Brisbane/59/2007 H1N1
H1-1933 A/WS/33 H1N1
H1-2009 A/California/6/2009 H1N1
H1-1918 A/South Caroline/1/18 H1N1
H2-1957 A/Canada/720/05 H2N2
H3-2003 A/Wyoming/3/03 H3N2
H3-2007 A/Brisbane/10/2007 H3N2
H5-2004 A/Vietnam/1194/2004 H5N1
H7-2003 A/Chicken/Netherlands/1/03 H7N7
H9-1999 A/Guinea fowl/Hong Kong/WF10/99 H9N2
doi:10.1371/journal.pone.0054890.t001
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Smaller rises in antibody titers were observed for all other seasonal
H1 viruses and to a lesser extent for H2 and H3. In persons with a
history of annual seasonal vaccination, the GMT at baseline was
higher than those without previous vaccination, but the magnitude
of response was much lower, and narrower, with seroconversion or
significant increase in titer largely limited to the H1-2009 antigen.
In persons without a history of seasonal vaccination, peak
responses were measured already at the time of the booster
vaccination with the pandemic vaccine, whereas this was not the
case for persons with a history of seasonal influenza vaccination:
here, the maximum change in titer was lower, and continued to
increase until the third time point of sampling, after the second
vaccine dose was given as seen in Figure 2. (Further described in
Table S2).
Discussion
In the present study, we compared antibody profiles in response
to infection and vaccination with influenza A(H1N1)pdm09 with a
PA. This technology was developed to enable comparative studies
using standardized assay format to reduce the problem of
variability and potentially interlaboratory differences in results of
HI and microneutralization testing by obviating the need for use of
biological reagents that are difficult to standardize, such as red
blood cells (for HI assays) or cells (for virus neutralization assays).
[15] We demonstrated that subjects with a history of seasonal
vaccination generally exhibited higher baseline titers for the
various HA antigens than subjects without such history. We also
show that the response differs according to the type of exposure:
following natural infection, a strong homologous response, and
weaker but significant increases in antibody titers to different HA1
antigens are seen, whereas the response following vaccination was
more restricted. These results need to be interpreted with caution,
because the mean age of the persons in the infection group was
lower, which in part could explain a more vigorous antibody
response. Remarkably, in both groups, responses in persons with a
history of vaccination were skewed towards older seasonal H1
antigens. These details were not evident from the kinetics in HI
titer, the method routinely used for evaluation of antibody
responses.
The study confirms that antibody response to infection and
vaccination are both shaped by prior exposure history, where prior
regular seasonal influenza virus vaccination had a clear effect on
the magnitude and kinetics of response to pandemic influenza
infection and vaccination. The higher GMTs at baseline were
particularly clear for antibodies binding to HA1 peptide from
recent seasonal influenza viruses, but slightly elevated levels were
also observed for antigens not offered through vaccination within
subtype H1. These reactivities may reflect the broadening of
antibody response with age. [15] An intriguing question is whether
such antibodies influence outcome of infection. Studies during the
pandemic have been inconclusive in this respect: The presence of
cross-neutralizing antibodies was limited to higher age groups, and
no protective effect was expected or observed in several studies.
[6,18,19] In contrast with this, some degree of cross protection
from severe illness by prior seasonal vaccination was suggested in
some studies. [20,21,22] Prior infection with an influenza A virus
can reduce morbidity and mortality caused by an infection with an
antigenically divergent influenza A virus because of heterosubtypic
immunity, both within and between subtypes. [23] Both natural
infection and seasonal vaccination can induce heterosubtypic
neutralizing antibodies, but our data suggest skewing against such
antibodies in persons with a history of seasonal vaccination.
[8,9,10] The immunological basis of heterosubtypic immunity is
not fully understood, but B cells, CD4+ and CD8+ T-cells and
mucosal immunity may contribute. [11,23] Passive serum transfer
showed that antibodies induced by seasonal influenza A(H1N1)
virus conferred protection in naı¨ve recipient mice against
A(H1N1)pdm09 challenge. The presence or absence of HI
antibodies, therefore, is not the sole indicator of the effectiveness
of protective cross-reactive antibody immunity. [24] In a mouse
model, Hillaire et al. [25], demonstrated that induction of T cells
specific for a seasonal H3N2 influenza virus led to protection
against infection with the antigenically unrelated A(H1N1)pdm09.
In addition, repeated infection with seasonal influenza virus
improved protection and clearance of influenza A(H1N1)pdm09
in ferrets. [26] In young children, a difference was observed in
levels of CD8+ T cells between vaccinated and unvaccinated
individuals, suggesting that the same mechanisms may apply in
humans as postulated by Bodewes et al. [27,28] The influenza
Table 2. Demographic characteristics of the subjects.
Characteristics All subjects
Not yearly vaccinated
with seasonal vaccine
Yearly vaccinated
with seasonal
vaccine
Natural infection with
H1N1(2009) without
earlier
seasonal vaccine
Natural infection with
H1N1(2009) with
earlier
seasonal vaccine
n =130 n = 58 n = 40 n =17 n = 15
Age - yrs.
Median 48 48 51 31 29
Range 12–66 28–61 25–66 14–60 12–66
Sex – no. (%)
Male 53 (40.8) 20 (34.5) 15 (37.5) 10 (58.8) 8 (53.3)
Female 77 (59.2) 38 (65.5) 25 (62.5) 7 (41.2) 7 (46.7)
Vaccinated since (%)
Before 2000 15 (37.5) Nk*
2000–2004 20 (50.0) Nk*
After 2004 5 (12.5) Nk*
*Not known.
doi:10.1371/journal.pone.0054890.t002
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pandemic of 2009 showed an unbalanced age distribution of
infected individuals, with a low incidence in elderly and a high
incidence in children. This could be partly explained by the lack of
heterosubtypic immunity, as a proportion of young children are
immunologically naı¨ve for influenza viruses. [6,29] However,
others described that low level heterosubtypic antibody responses
following seasonal influenza vaccination could offer immune
protection against antigenically distinct influenza viruses to a
certain extent. [9,10,30] The observations above imply that
seasonal influenza vaccines should also be evaluated for their
capacity to mimic the balance in response triggered by wild type
infection. Studies from Skowronski et al. [31,32] suggested an
increased risk of illness in persons with a history of seasonal
influenza vaccination during the pandemic, which potentially
could be explained by reduced levels of cross protective antibodies
or T cells as a result of reduced wild type infection.
Conclusions
In this study, we show that a history of seasonal influenza
vaccination has different effects on infection and vaccination
response. In vaccinees, the level of antibodies to the homologous
strain was reduced in persons with a history of vaccination,
whereas the reverse was true for infected persons. In both groups,
however, the antibody response was skewed against heterologous
antigens. More research is needed to understand if these
observations are relevant for susceptibility of the individuals for
Figure 1. HI versus PA for influenza A(H1N1)pdm09 in the natural infection-group and in the vaccination group. A. GMTs of influenza
A(H1N1)pdm09 for HI versus PA in the natural infection-group, with and without prior seasonal vaccination at time point 0 represents baseline, time
point 1 represents 10 days after day of onset of influenza symptoms and time point 2 represents 30 days after day of onset of influenza symptoms. B.
GMTs of influenza A(H1N1)pdm09 for HI versus PA in the vaccination group, with and without prior seasonal influenza vaccination at time point 0
represents baseline, time point 1 represents 3 weeks after the first vaccination and before the second vaccination and time point 2 represents 5
weeks after the second vaccination. Y axis denotes average GMT (adjusted for gender and age).
doi:10.1371/journal.pone.0054890.g001
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infection and disease. We also conclude that improved assessment
of the quality of immune response is needed when evaluation
current and potential influenza vaccines.
Supporting Information
Table S1 Geometric mean titers (GMT) at baseline and
after natural infection with pandemic influenza H1 2009.
Figure 2. Geometric mean titers (GMT) at time point 1 and 2 of the natural infection-group and in the vaccination group with and
without former seasonal influenza vaccination. A. GMTs for the various influenza HA1 antigens in patients infected with pandemic influenza
H1 2009, with and without a history of seasonal vaccination at time point 1 (10 days after day of onset of influenza symptoms) and time point 2 (30
days after day of onset of influenza symptoms). B. GMTs for the various influenza HA1 antigens in subjects vaccinated with inactivated MF-59
adjuvated pandemic Influenza A virus (H1N1) 2009, with and without a history of seasonal influenza vaccination at time point 0, 1 (3 weeks after the
first vaccination and before the second vaccination) and time point 2 (5 weeks after the second vaccination). Y axis denotes average GMT (adjusted
for gender and age).
doi:10.1371/journal.pone.0054890.g002
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GMT estimates are expressed as fold change for GMTs in persons
with and without a history of seasonal vaccination (GMTvacci-
nated/GMTnonvaccinated).
(DOC)
Table S2 Geometric mean titers (GMT) at baseline and
after vaccination with pandemic H1 2009 vaccine of
persons with and without a history of seasonal vaccina-
tion.
(DOC)
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